Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study

Similar documents
DAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination

Shorter Durations and Pan-genotypic Regimens The Final Frontier. Professor Greg Dore

Supplementary appendix

HCV screening in Australia What we do now, and what we hope to do in future? Professor Gregory Dore

HCV: how do we reach elimination from a clinicians perspective. A/Professor Gail Matthews

Australasian Professional Society on Alcohol and other Drugs, Annual Conference 2016 Sydney Australia

HIV/Sexual Health Clinical Education Session.

Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4

We know DAAs work for PWID, now what? Simplifying HCV testing, linkage to care and treatment

Stable incidence of hepatitis C virus infection among PWID in an Australian prison setting, : the HITS-p study

in chronic hepatitis C in Australia

Update in hepatitis C virus infection

RECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS

The single tablet regimen of ledipasvir/sofosbuvir is efficacious and well-tolerated among people receiving opioid substitution therapy

Will HCV therapies deliver global impact? Professor Greg Dore

Cunningham et al. BMC Infectious Diseases (2017) 17:420 DOI /s

Comparison of HCV Recurrent Viremia Rates in All-Oral and Interferon-Based Regimens

9/29/2014. Patterns of hepatitis C virus RNA levels during acute infection: the InC 3 study. Background. Background. Background

Eliminating Hepatitis C by 2030 Enhancing Prevention, Care and Treatment Among People who Inject Drugs

Treatment of Hepatitis C in People Who Inject Drugs (PWIDs) Andrew Seaman, MD OHA P&T Meeting January, 2017

Strategies to Enhance the Hepatitis C Care Cascade Among People Who Inject Drugs

La dernière frontière : simplification et intégration des soins

ACKNOWLEDGEMENTS. This study was funded by Merck & Co., Inc.

Annual Report 2016/17

Developing the campaign

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients

ICVH 2016 Oral Presentation: 28

Centre for Social Research in Health, UNSW Australia, NSW, Australia

Hepatitis C Resistance Associated Variants (RAVs)

Abstract LB-12. POLARIS-2: Pangenotypic Single Tablet Regimen with Inhibitors of HCV NS5B (Nucleotide) + NS5A + NS3

Update on Hepatitis C. Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017

C-CREST study, Part A: GZR + EBR or MK MK-3682 for genotypes 1, 2 and 3 - Phase II

Update on HCV Treatment

We extend our gratitude to the patients, their families, investigators and site personnel who participated in this study.

Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos

Treatment of Hepatitis C GT 3

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1

A Growing Epidemic: Hepatitis C in Drug Users

TREATMENT OF GENOTYPE 2

Ledipasvir-Sofosbuvir (Harvoni)

Update on Real-World Experience With HARVONI

Recent data in. treatment of acute hepatitis C. Christoph Boesecke Department of Medicine I Bonn University Hospital Bonn, Germany

EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

Update on Real-World Experience With HARVONI

Cases: Issues in Hepatitis C in Active or Recently Active Substance Abuse and Renal Failure

Clinical Management: Treatment of HCV Mono-infection

Hepatitis C Elimination: Australia s progress

Felice Nava, MD, PhD Felice A. Nava, MD PhD

TREATMENT OF RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION (ATAHC II)

HCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London

HEPATITIS C: CANADIAN CONTEXT

Hepatitis C reinfection after sustained virological response in HIV/HCV co-infected patients

Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2

ABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0162. Referring to Part of Dossier: Volume: Page:

National Clinical Guidelines for the treatment of HCV in adults. Version 5

New developments in HCV research and their implications for front-line practice

CURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA

Case study: the changing IV drug use problem/pattern and what that means to the epidemic

Barriers to Management of HCV: Treating People Who Use Drugs. May 9, 2015

International Network on Hepatitis in Substance Users

New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret

Section 7: Providing HCV testing and treatment to people who inject drugs

Global Declaration to Eliminate Hepatitis C in People Who Use Drugs

Transmission. Transmission Counseling

Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study

Professor Mark Nelson. Chelsea and Westminster Hospital, London, UK

29/09/2014. Expanding access to hepatitis C treatment through primary care: Challenges and opportunities. Disclosures

PIB. Next Generation Direct-Acting Antivirals. Collectively: G/P. Pibrentasvir (formerly ABT-530) pangenotypic NS5A inhibitor

Why make this statement?

Evolution of Therapy in HCV

The ASTRAL Program Abstracts LB-2, LB-12, 205, 209

Treatment of Patients with HCV and HIV

Latest Treatment Updates for GT 2 and GT 3 Patients

Treating HCV After Liver Transplantation: What are the Treatment Options?

HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA

Treatment as prevention in HCV: Modelling impact among people who inject drugs and HIV+ men who have sex with men

Treating HCV Genotype 2 & 3

Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection

2.0 Synopsis. ABT-450/r, ABT-267 M Clinical Study Report R&D/17/0539. (For National Authority Use Only)

HCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland

Epclusa (Sofosbuvir/Velpatasvir) for HIV/HCV

Models of care for management of HCV among PWID. Philip Bruggmann Switzerland

Heroin use is associated with progression to cirrhosis in HIV-HCV co-infected patients

New York State HCV Provider Webinar Series

Genotype 4, finally cured? Imam Waked Professor of Medicine National Liver Institute

Modeling what is required to prevent HIV and HCV among people who inject drugs in the U.S.

SYNOPSIS Final Clinical Study Report for Study AI444031

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

Learning Objective. After completing this educational activity, participants should be able to:

Harvoni: solution to HCV

National Clinical Guidelines for the treatment of HCV in adults. Version 4

National Clinical Guidelines for the treatment of HCV in adults. Version 3

HCV treatment in Australia: a new role for GPs

AUSTRALIAN NSP SURVEY NATIONAL DATA REPORT

How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France

Clinical guidelines for the treatment of hepatitis C in Iceland

Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis

New combination EBR/GZR: The end of an era for the difficult to treat?

Transcription:

Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study Olav Dalgard Professor dr med Akershus University Hospital and Oslo University Hospital, Norway Jason Grebely 1, Olav Dalgard 2, Brian Conway 3, Evan Cunningham 1, Philip Bruggmann 4, Behzad Hajarizadeh 1, Janaki Amin 5, Philippa Marks 1, Sophie Quiene 1, Tanya L Applegate 1, Julie Bruneau 5, Margaret Hellard 6, Alain Litwin 7, Tracy Swan 8, Jude Byrne 9, Melanie Lacalamita 10, Adrian Dunlop 11, Gail V. Matthews 1,12, Jeff Powis 13, David Shaw 14, Maria Christine Thurnheer 10, Martin Weltman 15, Ian Kronborg I 16, Curtis Cooper C 17, Jordan J Feld 18, Chris Fraser 19, John Dillon 20, Phillip Read 21, Ed Gane 22 and Gregory J Dore 1,12 on behalf of the SIMPLIFY Study Group 1 The Kirby Institute, UNSW Sydney, Sydney, Australia, 2 Akershus University Hospital, Oslo, Norway, 3 Vancouver Infectious Diseases Center, Vancouver, Canada, 4 Arud Centres for Addiction Medicine, Zurich, Switzerland, 5 Centre Hospitalier de l'université de Montréal, Canada, 6 The Burnet Institute, Melbourne, Australia, 7 Montefiore Medical Centre, New York, United States, 8 International Network on Hepatitis in Substance Users, New York, United States, 9 Australian Injecting & Illicit Drug Users League, Canberra, Australia 10 Poliklinik für Infektiologie, Inselspital, Bern, Switzerland, 11 Newcastle Pharmacotherapy Service, Newcastle, Australia, 12 St Vincent s Hospital, Sydney Australia, 13 South Riverdale Community Health Centre, Toronto, Canada, 14 Royal Adelaide Hospital, Adelaide, Australia, 15 Nepean Hospital, Penrith, Australia, 16 Footscray Hospital, Footscray, Australia, 17 Ottawa Hospital Research Institute, Ottawa, Canada, 18 Toronto General Hospital, Toronto, 19 Coolaid Community Health Centre, Victoria, Canada, 20 Ninewells Hospital, Dundee, United Kingdom, 21 Kirketon Road Centre, Sydney, Australia, 22 Auckland Hospital, Auckland, New Zealand Ġrebely et al. Lancet Gastro Hepatol 2018

Background/rationale DAA therapy is effective in people receiving OST 1-7 and people with a history of injecting drug use (including current/former people who inject) 7-16 Ongoing concern from some clinicians regarding DAA efficacy and risk of HCV reinfection among recent PWID In some settings in the US 17-18 and Europe 19, DAA reimbursement restrictions are in place for recent PWID Recent PWID excluded from most HCV phase II/III protocols There are little data on DAA outcomes among recent PWID 1) Grebely J, ILC 2017, Amsterdam, The Netherlands, April 19-23 rd, 2017 (FRI-236). 2) Grebely CID 2016. 3) Grebely CID 2016. 4) Grebely J, ILC 2017, Amsterdam, The Netherlands, April 19-23 rd, 2017 (FRI-235). 5) Zeuzem, S. Ann Intern Med 2015. 6) Dore, GJ Ann Intern Med 2016. 7) Grebely, Hajarizadeh, and Dore Nature Rev Gastro Hepatology 2017. 8) Norton B, et al. Int J Drug Policy In Press 2017; 9) Hull M, et al. INHSU 2016. 10) Conway AASLD 2016. 11) Bouscaillou EASL 2017. 12) Powis J. Int J Drug Policy 2017. 13) Read P. Int J Drug Policy 2017; 14) Litwin AL, et al. ILC 2017, Amsterdam, The Netherlands, April 19-23rd, 2017; 15) Sulkowski M, et al. ILC 2017, Amsterdam, The Netherlands, April 19-23rd, 2017. 16) Mazhnaya Int J Drug Policy In Press 2017. 17) Barua Ann Int Med 2017. 18) Ooka Am J Gastroenterol. 2017. 19) Marshall, AD et al. INHSU 2017, New York, United States, Sept 6-8, 2017.

SVR 12 (%) SVR12 among former/recent PWID 100 80 96% 89% 95% 88% 87% 82% 95% 90% 86% 60 40 20 0 44 46 89 100 93 98 215 244 60 69 59 72 142 150 88 98 971 1126 Norton Hull Conway Bouscaillou Powis Read 2017 1 2016 2 2016 3 2017 4 2017 5 2017 6 Litwin 2017 7 Sulkowski 2017 8 Mazhnaya 2017 9 1) Norton B, et al. Int J Drug Pol 2017. 2) Hull M, et al. INHSU 2016. 3) Conway AASLD 2016. 4) Bouscaillou EASL 2017. 5) Powis J. Int J Drug Policy 2017. 6) Read P. Int J Drug Policy 2017; 7) Litwin AL, et al. ILC 2017, Amsterdam, The Netherlands, April 19-23 rd, 2017; 8) Sulkowski M, et al. ILC 2017, Amsterdam, The Netherlands, April 19-23 rd, 2017. 16) Mazhnaya Int J Drug Policy In Press 2017.

Study Design Investigator-initiated, Kirby/UNSW sponsored, international open-label trial 17 sites, 7 countries Study recruitment conducted through a network of drug and alcohol clinics (n=3), hospital clinics (n=12), private practice (n=1) and community clinics (n=1) Participants enrolled between April 2016 and October 2016

Study design and participant eligibility DAA treatment-naïve patients with GT1-6 chronic HCV infection (F0-4) People with recent injecting drug use (past six months) Participants with HIV and decompensated liver disease excluded Electronic blister packs to monitor adherence Week 0 Week 12 Week 24 3 yrs Sofosbuvir/velpatasvir 400/100 mg od, n=103 SVR 12 Six-monthly follow-up for reinfection

Study endpoints and statistical analysis SVR12 was the primary efficacy endpoint (intent-to-treat) HCV RNA levels measured on local testing and confirmed by central testing with the Abbott RealTime HCV Viral Load assay (Abbott Molecular, lower limit of quantification of 12 IU/mL) Adherence Measured using an electronic blister-pack Calculated by dividing the number of total doses received during therapy by the total expected number of doses Participants completed a self-administered questionnaire to collect information on demographics, drug and alcohol use, and injecting risk behaviours Detailed information on adverse events

Participant characteristics SOF/VEL (12 weeks) Characteristic N = 103 Female, n (%) 29 (28%) Age, median years (25%, 75%) 48 (41, 53) Any injecting drug use (last 30 days), n 76 (74%) (%) Heroin 57 (55%) Methamphetamines 31 (30%) Other opioids 22 (21%) Cocaine 13 (13%) >Daily injecting drug use (last 30 days), n (%) 27 (26%) Current opioid substitution therapy, n (%) Methadone 45 (44%) Buprenorphine + naloxone 16 (16%)

Participant characteristics SOF/VEL (12 weeks) Characteristic N = 103 HCV genotype, n (%) 1 36 (35%) 2 5 (5%) 3 60 (58%) 4 2 (2%) Fibrosis stage (METAVIR), n (%) F0-F1 59 (62%) F2-F3 27 (28%) F4 9 (9%) Study site distribution, n (%) Canada/US 40 (39%) Europe 20 (19%) Australasia 43 (42%)

Participant disposition Assessed for eligibility (n=114) Started treatment Included in intentionto-treat analysis (n=103) Excluded (n=11) Lost to follow-up (n=3) Patient refused (n=2) HCV RNA negative (n=2) Laboratory parameters (n=3) Other, not specified (n=1) Did not complete treatment (n=3) Lost to follow-up (n=2) Death due to overdose (n = 1) Completed treatment (n=100) Analysed (n=103) Efficacy: 103 Safety: 103

Response (%) SVR12: Intent-to-treat 100 90 80 96% 94% 70 60 50 40 30 20 10 0 99/103 ETR 97/103 SVR12 No cases of virological failure/viral relapse, 1 participant lost to follow-up between ETR and SVR12 1 case of reinfection (1a-1a, % nucleotide: NS5A, 10.1%; NS5B, 4.6%, Core-E2, 12.0%)

Injecting drug use during therapy

Impact of injecting drug use and OST on SVR12

Median adherence: 94% Mean adherence: 89% Legend. Daily adherence to sofosbuvir and velpatasvir as measured by weekly electronic blister packs (n=103). Each row represents an individual patient and each column represents one day of therapy. Green boxes represent dose received, yellow boxes represent no dose received, and white box represent early treatment discontinuation. Light green boxes represent the pill counts when a blister pack was damaged in which no pills were returned. There were no cases of virological failure or viral relapse.

Cunningham EB, et al In Preparation

Discontinuations and adverse events SOF/VEL (12 weeks) Characteristic N = 103 AE leading to treatment discontinuation of, n (%) 1 (1%) Serious adverse event, n (%) 7 (7%) Any adverse event, n (%) 80 (78%) Common adverse events, n (%) Fatigue 23 (11%) Headache 19 (9%) Nausea 13 (6%) Insomnia 9 (4%) Arthralgia 6 (3%)

HCV reinfection One case of HCV reinfection over 38 person-years follow-up for a reinfection rate of 2.7 cases per 100-person-years (95% CI, 0.1-13.8) 55 year old male - smoking cocaine and injecting morphine 2-3 times most days in the last month at baseline, but reported using sterile injecting equipment for all injections HCV genotype 1a prior to initiating therapy, was negative at ETR, and had recurrent viraemia with HCV genotype 1a at SVR12 During treatment - ongoing injecting morphine (frequency of >3 times per day) at the end of treatment, but reported using sterile injecting equipment for all injections Sequencing and phylogenetic analysis was consistent with reinfection with HCV genotype 1a (nucleotide divergence NS5A, 10.1%; NS5B, 4.6%; Core-E2, 12.0%).

Summary and conclusions Among recent PWID (past six months) with chronic HCV genotypes 1-4 treated with sofosbuvir and velpatasvir, SVR12 was 94% There was no impact of injecting drug use or OST at treatment initiation Analyses are underway to evaluate the impact of on-treatment drug use There were no cases of virological failure or viral relapse, but one case of HCV reinfection was observed These data provide support for DAA HCV treatment among recent PWID Further studies are needed in people with more recent injecting and people with HCV/HIV co-infection